COMPASS Pathways (NASDAQ:CMPS) Announces Earnings Results

COMPASS Pathways (NASDAQ:CMPS) issued its earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.04, Zacks reports. During the same period last year, the business earned ($0.67) earnings per share.

COMPASS Pathways Stock Performance

NASDAQ:CMPS traded down $0.01 during midday trading on Friday, reaching $4.75. The stock had a trading volume of 2,081,860 shares, compared to its average volume of 874,967. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03. The firm’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $7.04. The stock has a market capitalization of $324.85 million, a P/E ratio of -2.16 and a beta of 2.29. COMPASS Pathways has a 1-year low of $4.05 and a 1-year high of $12.75.

Insider Buying and Selling

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares in the company, valued at $41,779,932.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.25% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on CMPS. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Canaccord Genuity Group dropped their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Royal Bank of Canada cut their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday. Maxim Group decreased their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday. Finally, HC Wainwright cut their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $30.67.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.